165 related articles for article (PubMed ID: 22024351)
1. Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients.
Rodriguez PC; Neninger E; García B; Popa X; Viada C; Luaces P; González G; Lage A; Montero E; Crombet T
J Immune Based Ther Vaccines; 2011 Oct; 9():7. PubMed ID: 22024351
[TBL] [Abstract][Full Text] [Related]
2. A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients.
Rodriguez PC; Popa X; Martínez O; Mendoza S; Santiesteban E; Crespo T; Amador RM; Fleytas R; Acosta SC; Otero Y; Romero GN; de la Torre A; Cala M; Arzuaga L; Vello L; Reyes D; Futiel N; Sabates T; Catala M; Flores YI; Garcia B; Viada C; Lorenzo-Luaces P; Marrero MA; Alonso L; Parra J; Aguilera N; Pomares Y; Sierra P; Rodríguez G; Mazorra Z; Lage A; Crombet T; Neninger E
Clin Cancer Res; 2016 Aug; 22(15):3782-90. PubMed ID: 26927662
[TBL] [Abstract][Full Text] [Related]
3. CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer.
Crombet Ramos T; Rodríguez PC; Neninger Vinageras E; Garcia Verdecia B; Lage Davila A
Expert Rev Vaccines; 2015; 14(10):1303-11. PubMed ID: 26295963
[TBL] [Abstract][Full Text] [Related]
4. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy.
Rodríguez PC; Rodríguez G; González G; Lage A
MEDICC Rev; 2010; 12(1):17-23. PubMed ID: 20387330
[TBL] [Abstract][Full Text] [Related]
5. Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule.
Popa X; García B; Fuentes KP; Huerta V; Alvarez K; Viada CE; Neninger E; Rodríguez PC; González Z; González A; Crombet T; Mazorra Z
Oncoimmunology; 2020 May; 9(1):1762465. PubMed ID: 32923124
[TBL] [Abstract][Full Text] [Related]
6. Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario.
Flores Vega YI; Páramo González DL; Alsina Sarmiento SC; Alsina Tul LE; Inguanzo Valdés IB; Rodríguez Machado J; Elejalde Larrinaga Á; Flores Rodríguez JE; Lamadrid García J; Corrales Otero D; Ropero Toirac R; Crombet Ramos T; Gracia Medina EA
J Cancer; 2023; 14(5):874-879. PubMed ID: 37056397
[No Abstract] [Full Text] [Related]
7. Safety and effectiveness of CIMAvax-EGF administered in community polyclinics.
Ortiz Carrodeguas RA; Lorenzo Monteagudo G; Guerra Chaviano PP; Álvarez Montané I; Salomón Saldívar EE; Lobaina Lambert L; Camacho Sosa K; Bermúdez Pino R; Blanco Mustelier P; Valdés Rodríguez E; González Piloto S; Guerra de la Vega A; Valdés Sánchez L; Montes De Santis A; Parra Zabala J; Viada González C; Calvo Aguilera N; Saavedra Hernández D; Santos Morales O; Crombet Ramos T
Front Oncol; 2023; 13():1287902. PubMed ID: 38304035
[TBL] [Abstract][Full Text] [Related]
8. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.
Neninger Vinageras E; de la Torre A; Osorio Rodríguez M; Catalá Ferrer M; Bravo I; Mendoza del Pino M; Abreu Abreu D; Acosta Brooks S; Rives R; del Castillo Carrillo C; González Dueñas M; Viada C; García Verdecia B; Crombet Ramos T; González Marinello G; Lage Dávila A
J Clin Oncol; 2008 Mar; 26(9):1452-8. PubMed ID: 18349395
[TBL] [Abstract][Full Text] [Related]
9. CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients.
Saavedra D; Crombet T
Front Immunol; 2017; 8():269. PubMed ID: 28348561
[TBL] [Abstract][Full Text] [Related]
10. CIMAvax-EGF: Toward long-term survival of advanced NSCLC.
Saavedra D; Neninger E; Rodriguez C; Viada C; Mazorra Z; Lage A; Crombet T
Semin Oncol; 2018 Jan; 45(1-2):34-40. PubMed ID: 30318082
[TBL] [Abstract][Full Text] [Related]
11. CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine.
Tagliamento M; Rijavec E; Barletta G; Biello F; Rossi G; Grossi F; Genova C
Expert Opin Biol Ther; 2018 Jul; 18(7):829-835. PubMed ID: 29936901
[TBL] [Abstract][Full Text] [Related]
12. A Novel Combined Conjugate Therapeutic Cancer Vaccine, Recombinant EGF-CRM197, in Patients With Advanced Solid Tumors: A Phase I Clinical Study.
Xiong AW; Fang JM; Ren SX; Li W; Wang J; Zhao Y; Chen GY; Xu Q; Zhou CC
Front Oncol; 2021; 11():745699. PubMed ID: 34804932
[TBL] [Abstract][Full Text] [Related]
13. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.
García B; Neninger E; de la Torre A; Leonard I; Martínez R; Viada C; González G; Mazorra Z; Lage A; Crombet T
Clin Cancer Res; 2008 Feb; 14(3):840-6. PubMed ID: 18245547
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials.
González G; Crombet T; Neninger E; Viada C; Lage A
Hum Vaccin; 2007; 3(1):8-13. PubMed ID: 17204867
[TBL] [Abstract][Full Text] [Related]
15. Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial.
Ramos TC; Vinageras EN; Ferrer MC; Verdecia BG; Rupalé IL; Pérez LM; Marinello GG; Rodríguez RP; Dávila AL
Cancer Biol Ther; 2006 Feb; 5(2):145-9. PubMed ID: 16357522
[TBL] [Abstract][Full Text] [Related]
16. The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer.
Crombet Ramos T; Santos Morales O; Dy GK; León Monzón K; Lage Dávila A
Front Oncol; 2021; 11():639745. PubMed ID: 34211836
[TBL] [Abstract][Full Text] [Related]
17. Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC.
Evans R; Lee K; Wallace PK; Reid M; Muhitch J; Dozier A; Mesa C; Luaces PL; Santos-Morales O; Groman A; Cedeno C; Cinquino A; Fisher DT; Puzanov I; Opyrchal M; Fountzilas C; Dai T; Ernstoff M; Attwood K; Hutson A; Johnson C; Mazorra Z; Saavedra D; Leon K; Lage A; Crombet T; Dy GK
Front Oncol; 2022; 12():958043. PubMed ID: 35992783
[TBL] [Abstract][Full Text] [Related]
18. Repeated dose intramuscular injection of the CIMAvax-EGF vaccine in Sprague Dawley rats induces local and systemic toxicity.
Mancebo A; Casacó A; González B; Ledón N; Sorlozabal J; León A; Gómez D; González Y; Bada AM; González C; Arteaga ME; Ramírez H; Fuentes D
Vaccine; 2012 May; 30(22):3329-38. PubMed ID: 22433960
[TBL] [Abstract][Full Text] [Related]
19. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer.
Neninger E; Verdecia BG; Crombet T; Viada C; Pereda S; Leonard I; Mazorra Z; Fleites G; González M; Wilkinson B; González G; Lage A
J Immunother; 2009 Jan; 32(1):92-9. PubMed ID: 19307998
[TBL] [Abstract][Full Text] [Related]
20. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial.
González G; Crombet T; Catalá M; Mirabal V; Hernández JC; González Y; Marinello P; Guillén G; Lage A
Ann Oncol; 1998 Apr; 9(4):431-5. PubMed ID: 9636835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
